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Background: Ropinirole prolonged release (RPR) is a once-daily formulation. However, there may be individual
pharmacokinetic differences so that multiple dosing may be preferred in some individuals. This study compares
once-daily and twice-daily RPR in patients with Parkinson’s disease.
Methods: This study was an open-label crossover study. We enrolled Parkinson’s disease patients on dopamine
agonist therapy with unsatisfactory control such as motor fluctuation, dyskinesia and sleep-related problems.
Agonists were switched into equivalent dose of RPR. Subjects were consecutively enrolled into either once-daily
first or twice-daily first groups, and received the same amount of RPR in a single and two divided dosing for
8 weeks respectively in a crossover manner without a washout period.
The primary outcome was a questionnaire of the preference completed by patients in the last visit. The secondary
outcome measures included the Unified Parkinson’s Disease Rating Scale part 3 (mUPDRS), Hoehn and Yahr stage
(H&Y); sleep questionnaire including overall quality of sleep, nocturnal off symptoms and early morning symptoms;
Epworth Sleep Scale (ESS); compliances and patient global impression (PGI).
Results: A total of 82 patients were enrolled and 61 completed the study. 31 patients preferred twice-daily
regimen, 17 preferred the once-daily regimen, and 13 had no preference. Their mean mUPDRS, H&Y, ESS, sleep
quality, compliance and adverse events were not statistically different in both regimens. PGI-improvement on
wearing off defined was better in twice-daily dosing regimen.
Conclusions: RPR is a once-daily formulation, but multiple dosing was preferred in many patients. Multiple dosing
of RPR might be a therapeutic option if once-daily dosing is unsatisfactory.
Trial registration: This study is registered with ClinicalTrials.gov, number NCT00986245.
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Ropinirole is a non-ergot D2/D3 agonist for the manage-
ment of Parkinson’s disease (PD). Ropinirole, when given
in the immediate-release (IR) form, has to be taken three
times a day. It is hypothesized that pulsatile stimulation of
dopamine receptors in PD may induce motor fluctuation
[1]. Theoretically, motor fluctuation can be avoided by
continuous stimulation of the dopamine receptors. Based* Correspondence: brain@snu.ac.kr
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reproduction in any medium, provided the oron this hypothesis, a prolonged-release (PR) formulation
was developed.
Ropinirole PR (RPR) is a once daily formulation of
ropinirole that is not inferior to the immediate-release
formulation [2]. In advanced PD patients, once-daily RPR
shows significantly greater improvement in parkinsonian
symptoms than IR from [3]. Once daily dosing provides
better medication compliance [4] and smoother plasma
levels than ropinirole IR (RIR) [5]. Therefore, this for-
mulation is regarded as valuable addition to available
antiparkinsonian medications [6,7].
However, we have met patients unsatisfied with once
daily RPR who had asked for multiple daily dosing in. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ropinirole level from Tompson et al. [5], the nocturnal
concentration may be lower in the once-daily RPR than
the three times daily RIR. The “off” symptoms between
dusk and dawn might be more severe in the once daily
RPR dosing than in the multiple daily RIR dosing. In
addition, the early morning off duration may be longer
in the RPR than in the RIR, since the increasing slope of
the plasma concentration is gentler in the RPR. Thus
multiple dosing with RPR may provide even better
control in some patients.
Herein, we compared the preference of patients for
once-daily versus twice-daily combination of RPR.
Methods
Patients
PD patients between 30 and 80 years of age were eligible
for the study. All subjects were taking a stable dose of
levodopa and dopamine agonist for at least 4 weeks
prior to the screening. They were on dopamine agonist
(RIR or pramipexole IR) and were considering changing
to RPR due to suboptimal control with levodopa and
dopamine agonist therapy, for example, motor fluctuation,
dyskinesia, and sleep-related problems.
There were no limitations on other antiparkinsonian
medications as long as the treatments remained stable
for at least 4 weeks prior to and throughout the study.
Neuroleptics were not allowed in this study. Patients
with significant or uncontrolled psychiatric, cognitive,
neurologic or other medical disorders; a history of severe
dizziness or fainting due to orthostatic hypotension; a
recent history or current evidence of drug abuse or
alcoholism; a history of severe adverse events related
dopaminergic agents; a history of allergic reaction to
the similar medications; and a history of heavy metal
poisoning were not eligible for the study. Patients wereFigure 1 Study design.excluded from the study if they had used RPR, or an
investigational medication within 4 weeks. We did not
enroll patients who were on less than 2 mg of RIR or
less than 0.375 mg of pramipexole IR since we could
not prescribe a twice-daily dose without splitting the
tablet shown in Additional file 1.Study design
This study was a two-centre, 16 week, two-period, open-
label crossover study between once daily and twice daily
dosing of RPR. The study protocol was approved by
Institutional Review Board of the Seoul National
University Hospital and the Seoul National University
Metropolitan Boramae Hospital and conformed to the
principles of the Declaration of Helsinki. All patients
signed an informed consent before participation in this
study.
Subjects were sequentially enrolled into once-daily
dosing first or twice-daily dosing first group. Each
group received 8-weeks of RPR once daily or twice
daily and then without a washout period switched into
twice daily or once daily dosing schedules for 8-weeks
in an open label fashion (Figure 1).
Conversion ratio between RIR and RPR was 1:1 and
pramipexole IR to RPR was 1:5. RPR comes in even
numbered sizes (2, 4, 8 mg/tablets). Therefore, upward
adjustment of the RPR dose was made when needed in
order not to break the RPR tablets. For example, when
RIR was given at 9 mg/d, RPR was given at 10 mg/d. In
twice daily dosing, we split the dose of the RPR into two
doses and split into unequal doses when needed in order
not to break the RPR tablets (for example, 10 mg into 6
and 4 mg, Table 1). First dosing of RPR was given with
the first dosing of the other antiparkinsonian medications.
The timing and dose of the second dosing was based
Table 1 Baseline characteristics
QD→ BID (N = 29) BID→QD (N = 32) P Value Overall (N = 61)
Age (years) 60.9 ± 9.8 61.1 ± 8.4 0.925 61.0 ± 9.0
Onset age 51.7 ± 10.8 51.8 ± 7.0 0.857 51.7 ± 8.9
Sex (M:F) 11:18 13:19 1.000 24:37
mUPDRS 20.0 ± 9.5 22.5 ± 8.6 0.170 21.3 ± 9.0
Hoehn and Yahr stage 2.1 ± 0.5 2.4 ± 0.7 0.063 2.2 ± 0.6
Ropinirole PR dose after titration 8.9 ± 5.6 11.0 ± 5.7 0.128 10.0 ± 5.7
LEDD 894.0 ± 392.8 865.9 ± 361.7 0.879 879.2 ± 373.9
Epworth Sleep Scale 6.1 ± 5.5 6.2 ± 5.9 0.353 6.1 ± 5.6
Sleep questionnaire
Overall sleep quality 3.8 ± 2.6 2.9 ± 2.7 0.232 3.4 ± 2.7
Nocturnal off-symptoms 2.5 ± 2.8 3.4 ± 3.7 0.659 3.0 ± 3.3
Early morning off symptoms 2.9 ± 2.7 3.0 ± 3.9 0.721 3.0 ± 3.8
QD, Once-daily; BID, Twice-daily; mUPDRS, Unified Parkinson’s Disease Rating Scale part 3; PR, prolonged-release; LEDD, levodopa equivalent dose.
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or in the late afternoon at a lower dosage.
Titration of RPR was allowed only in the initial 4 weeks
in the first period of each sequence. The dose was titrated
until an optimal therapeutic response was achieved or
intolerable adverse effects disappeared. The dosing
frequency was maintained during the titration phase.
Once an optimal dose was achieved, the subject was
maintained on that dose for the remainder of the treatment
phase. Changes in other antiparkinsonian medications
were not allowed. In the second period in each sequence,
the titration of RPR was not allowed. However, if the
subject complained of intolerable off-symptoms, dyskin-
esia or adverse effects, early completion was accepted
after the last visit earlier than the planned 16 weeks.
Scheduled study visits were baseline and week 8 and
16. Patients were allowed to make non-scheduled visits
when needed. At the baseline visit, all subjects were
assessed with the Unified Parkinson’s Disease Rating
Scale part 3 (mUPDRS) and Hoehn and Yahr stage (H&Y)
with a medication-on state, sleep questionnaire including
overall quality of sleep, nocturnal off symptoms and early
morning motor symptom; Epworth Sleep Scale (ESS).
In the sleep questionnaire, we used the visual analogue
scale ranging from 0 (perfect imaginable quality of sleep)
to 10 (worst imaginable quality of sleep).
After 8 and 16 weeks or at last visit for early completion,
all assessments were repeated and the Patient’s Global
Impressions (PGI) and compliance to the prescribed doses
were obtained. Medication compliance was recorded.
During each period, mean compliance rates were calcu-
lated based on the total prescribed doses and total actually
taken doses for all subjects during each period. Adverse
events (AEs) and changes in wearing-off and dyskinesias
were followed throughout the study. Preference for
dosing schedule was asked at the completion of thestudy. The preference was assessed with a question:
“which regimen do you prefer?” Available answers were
“I prefer the once a day”; “I prefer the twice a day”; “I
do not prefer one treatment over the other.” In
addition, the reasons for the preference were also
asked.
If subjects completed the study earlier than the com-
pletion of the second treatment period, they were asked
for their preferences and evaluated at the discontinuation
visit. Patients who discontinued during the first treatment
period or did not complete the questionnaire for the
preference were excluded from the analysis.
Outcome measures
Primary outcome measure was the preference of the
subjects between once-daily versus twice-daily of RPR at
the completion or at early completion after crossover.
Secondary outcome measures included the mUPDRS
and H&Y at the medication-on state; sleep questionnaire
including overall quality of sleep, nocturnal off symptoms
and early morning motor symptoms; ESS; Compliance;
and PGI of improvement (PGI-I). Additional secondary
outcome measures were the proportion of patients who
answered ‘improvement’, ‘stationary’ or ‘aggravated’ for each
period and the severity of the wearing-off and dyskinesia.
As safety measures, AEs were followed throughout the
study. This study is registered with ClinicalTrials.gov,
number NCT00986245.
Statistical analyses
Comparisons between the Sequences once daily to twice
daily (1→ 2) and twice daily to once daily (2→ 1) for
baseline were analyzed using Mann–Whitney test. For
the primary analysis, descriptive statistics were used to
determine subject preferences. Comparisons between
groups that preferred once-daily or twice-daily were
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tween once-daily and twice-daily phases in mUPDRS,
H&Y, PGI-I, sleep questionnaire, ESS, compliance and
changes in the wearing-off and dyskinesias were analyzed
with Wilcoxon signed rank comparisons. McNemar tests
were used to evaluate differences in AE between once-
daily and twice-daily phases.
Statistical analyses were done with SPSS statistical
package version 19 (SPSS Inc., Chicago, IL, USA).
Results
Subjects and discontinuations
A total of 82 patients with PD were enrolled in this
study at two centres in Seoul, Korea. The first subject
was enrolled in September 2009 and the last subject
completed the study in December 2010. Forty one
patients started with once-daily dosing and another 41
patients with twice-daily dosing. Baseline demographics
were much the same in both treatment groups (Table 1).
Twenty one subjects (25.6%) did not complete this study
(Figure 2). The most common reason for discontinuation
was poor compliance. The discontinuation rate was higher
in Sequence 1→ 2 (respectively, 12 in sequence 1→ 2Figure 2 Subject flow chart.vs. 9 in sequence 2→ 1); however, it was not statistical
significant. One patient was excluded because he was
unknowingly on levosulpride. According to dosing fre-
quency, ten subjects dropped out from the once-daily
period and ten from the twice-daily period. According
to the sequence, eighteen patients dropped out during
the first period and three during the second period in
each sequence. A total of sixty one subjects (74.4%)
were included in the final analysis (Figure 2).
At the baseline visit, twenty four patients were on RIR
(4.9 ± 2.2 mg/day) and thirty seven on pramipexole IR
(2.4 ± 1.0 mg/day). Based on the conversion ratio, the
dose of RIR and pramipexole IR was calculated as RPR
9.1 ± 5.0 mg/day. In order to avoid breaking the RPR
tablets, the actual converted dose using Table 1 was
10.0 ± 5.7 mg/day before titration. After the titration, the
average dose of RPR was 10.7 ± 6.2 mg/day.
Primary outcome
In response to the final preference questionnaire, 28%
(n = 17) of the patients preferred the once-daily regimen,
51% (n = 31) preferred the twice-daily regimen, and 21%
(n = 21) did not have a preference (Figure 3).
Figure 3 Patient’s preferences and reasons.
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(Figure 3), the preference reasons were better on-quality
(n = 8), more tolerable off-symptoms (n = 5), less intolerable
dyskinesia (n = 4) and convenience (n = 4). The reasons
for preferring the twice-daily regimen were (Figure 3):
more tolerable off-symptoms (n = 21), less intolerable
dyskinesia (n = 8), decreased AEs (n = 6), on-quality (n = 3),
psychological stability (n = 3) and sleeping well (n = 1).
Secondary outcomes
Their mean mUPDRS, H&Y, ESS, sleep quality, PGI,
compliance and AEs were not statistically different
between the two regimens (Table 2).
As for PGI, 50/61 reported improvement after switching
to RPR from the IR form of agonists, whereas noneTable 2 Secondary outcomes
Once-daily Twice-daily P Value
mUPDRS 17.5 ± 8.2 17.1 ± 8.9 0.324
Hoehn and Yahr stage 2.1 ± 0.6 2.1 ± 0.6 0.260
Excessive daytime sleepiness 6.3 ± 5.2 6.4 ± 4.8 0.498
Compliance (%) 98.4 ± 3.9 97.6 ± 3.8 0.112
Sleep questionnaire
Overall quality of sleep 2.9 ± 2.6 3.2 ± 2.5 0.307
Nocturnal off-symptoms 2.9 ± 3.2 3.1 ± 3.2 0.396
Early morning off symptoms 2.5 ± 3.3 2.9 ± 3.2 0.384
PGI-I, no (%)
Overall 32 (52.5) 42 (68.9) 0.078
Off duration 27 (44.3) 38 (62.3) 0.035a
Worst wearing-off severity 28 (45.9) 34 (55.7) 0.238
Dyskinesia duration 13 (21.3) 16 (26.2) 0.549
Dyskinesia severity 16 (26.2) 15 (24.6) 1.000
aP <0.005.
mUPDRS, Unified Parkinson’s Disease Rating Scale part 3; PGI-I, patient global
impressions of improvement.reported deterioration in PGI for both regimens. There-
fore, RPR was able to achieve significant improvement
over the IR form of agonists. In the once-daily period,
8.2% (n = 5) had moderate improvement, 44.3% (n = 27)
mild improvement, 32.8% (n = 20) no change, 13.1%
(n = 8) mild deterioration, and 1.6% (n = 1) moderate
deterioration. In the twice-daily period, 1.6% (n = 1)
had marked improvement, 14.8% (n = 9) moderate im-
provement, 52.5% (n = 32) mild improvement, 18.0%
(n = 11) no change, 9.8% (n = 6) mild deterioration,
and 3.3% (n = 2) moderate deterioration. At the end of
each period, the proportions of PGI-I were not statistically
different (P = 0.078, Table 2).
For wearing off, in the once-daily regimen, 44.3% (n = 27)
had decreased off-duration and 14.8% (n = 9) had increased
off-duration. In the twice-daily regimen, the off-duration
was decreased in 62.3% (n = 38) and increased in 6%
(n = 9.8) of the subjects. The PGI-I of off-duration was
significantly higher in twice-daily regimen (P = 0.035).
For the worst wearing-off quality, there was no significant
difference in PGI-I (P = 0.238). For dyskinesia, the
duration and severity had no statistical difference in
the once-daily and twice-daily regimens (P = 0.549 and
P = 1.000).Adverse events
The incidence of drug-related AEs did not differ between
the once-daily (54.1%, 33/61) and twice-daily (45.9%,
28/61) regimens (P = 0.227, Additional file 2). The most
common drug-related AEs for the respective regimens
were constipation (respectively, once-daily vs. twice-daily,
32.8%, 20/61 vs. 31.1%, 19/61), nausea (14.8%, 9/61 vs.
11.5%, 7/61), dyspepsia (11.5%, 7/61 vs. 9.8%, 6/61),
dizziness (4.9%, 3/61 vs. 6.6%, 4/61), headache (4.9%,
3/61 vs. 1.6%, 1/61), aggravated REM sleep behavior
disorder (3.3%, 2/61 vs. 3.3%, 2/61), hypersomnolence
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4.9%, 3/61), agitation (1.6%, 1/61 vs. 1.6%, 1/61), and
vivid dream (1.6%, 1/61 vs. 0%, 0/61).
Sixty patients chose to remain on RPR, but only one
patient reverted back to pramipexole IR to take at the
same time with other antiparkinsonian medications.
Discussion
RPR is a once daily oral dopamine agonist for PD. In
general, it is prescribed as a once daily regimen. When
patients switched from once-daily to twice-daily or twice-
daily to once-daily, however, their mean mUPDRS,
H&Y, ESS, sleep quality and AEs were not statistically
different. Despite the different dosing frequency, these
findings indicate the same dose of RPR had a similar
efficacy without an increase in AEs and was not inferior.
To check for bias of the sequence effect, we analyzed
the outcomes based on the order. When the once-daily
regimen was administered first (sequence 1→ 2), 51.79%
(15/29) of the patients preferred the twice-daily regimen.
The proportion of subjects who preferred the twice-daily
regimen more was 50% (16/32) when the twice-daily
regimen was administered first (sequence 2→ 1). Thus
there was no sequence effect. We also did not find a
sequence effect in the secondary outcome analysis.
For PGI-I, 50 patients reported improvement after
RPR over the IR form of agonists. Admittedly, the dose
was increased from 9.1 ± 5.0 mg of the IR form of agonists
to 10.7 ± 6.2 mg of RPR. It is to be noted that we tried
to optimize the medication with the available IR form
of agonists balancing many factors such as motor fluctu-
ation, dyskinesia and adverse effects. Therefore, it is defin-
itely a benefit of RPR when the condition of patients’
improved even with the increased mean daily dose being
within tolerance.
In our study, PD patients preferred the twice-daily
regimen to the once-daily regimen (51% vs. 28%). In
patients who preferred the twice-daily regimen, their
main reasons were decreased severity of off symptoms or
dyskinesia and decreased AEs. Especially for wearing-off
duration, the PGI-I was significantly higher in twice-daily
regimen. Thus, we should consider the twice daily regimen
with its reduced severity of symptoms or decreased
intolerable AEs for antiparkinsonian medications.
When patients chose the once-daily regimen, their
main reason was improved on quality and decreased off
symptoms or dyskinesia. Thus, we should consider the
once daily regimen preferentially for young patients
who are active workers in the daytime or have diphasic
dyskinesia.
We expected changes in sleep quality and daytime
sleepiness between the two regimens. However, there
were no significant differences between the once-daily
and twice-daily regimens.As can be seen in the time window of the ropinirole
level from Tompson et al. [5], the nocturnal concentration
may be lower in the once daily RPR than the three times
daily RIR. The down sloping of the ropinirole level was
designed taking into consideration natural dopaminergic
stimulation and improvement in nocturnal side effects
including insomnia and hallucinations. Additionally,
the reason was not fully explained by the time window
of the ropinirole level in the steady state. However,
multiple dosing of RPR may provide even better control
in some patients.
Although patients showed no differences in their mean
mUPDRS, H&Y, ESS, sleep quality and AEs, more patients
preferred the twice-daily regimen and their main reason
was more tolerable off-symptoms. Three of our study
patients preferred the twice-daily regimen due to psycho-
logical stability, and decreased anxiety due to reduced off
symptoms. This finding shows that psychological factors
may explain the preference. Patients in this study previ-
ously maintained dopaminergic therapy with multiple
dosing. They endured off symptoms and have fear of
them. Therefore, as an ostensible reason of preference,
they chose “more tolerable off-symptoms”, however the
real reason would be “decreased anxiety due to reduced
off symptoms.”
In antiparkinsonian medication, once daily dosing may
improve compliance and achieve the desired outcome
[5]. Four patients chose the once daily regimen due to
convenience. However, almost all PD patients are taking
multiple antiparkinsonian medications many times a
day. Thus, compliance may not be a big issue especially
for advanced PD patients.
Conclusions
In this study, RPR was able to achieve improvement over
the IR form of agonists. Twice-daily RPR was preferred
over once-daily dosing in many patients.
This study has limitations as an open-label trials and
pharmacodynamical study was not done. However,
multiple dosing of RPR might be considered a thera-
peutic option if once-daily dosing is unsatisfactory.
Greater satisfaction with twice-daily RPR may lead to
achieving good compliance and improving outcomes.
In response to the final preference questionnaire, 28%
(n = 17) of the patients preferred the once-daily regimen,
51% (n = 31) preferred the twice-daily regimen, and 21%
(n = 21) did not have a preference.Additional files
Additional file 1: Dose switches from conventional dopamine
agonists to ropinirole PR.
Additional file 2: Adverse events.
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